Literature DB >> 3046824

Metabolic and cardiovascular effects of infusions of low doses of isoprenaline in man.

P I Mansell1, I W Fellows, A T Birmingham, I A Macdonald.   

Abstract

1. The cardiovascular and metabolic responses to low doses of isoprenaline (15 and 5 ng min-1 kg-1 body weight infused over 30 min) were determined in six healthy males. The study was performed to investigate whether there were sustained effects after the termination of the isoprenaline infusion, as has been observed previously after the infusion of adrenaline. 2. The isoprenaline infusions produced dose-dependent increases in heart rate, systolic blood pressure and metabolic rate, but similar increases in calf blood flow and decreases in diastolic blood pressure for the two infusion rates. Finger tremor was increased in amplitude by the 15 ng min-1 kg-1 infusion only. The changes in each of these physiological variables largely resolved within a few minutes of discontinuing the isoprenaline infusions. 3. There were no changes in arterialized venous plasma adrenaline or noradrenaline levels during the isoprenaline infusions. Mean peak plasma isoprenaline levels were 0.16 +/- 0.02 nmol/l during the 5 ng min-1 kg-1 infusion and 0.71 +/- 0.05 nmol/l during the 15 ng min-1 kg-1 infusion. 4. Plasma insulin levels increased with isoprenaline but blood glucose concentrations were unchanged, consistent with a direct effect of isoprenaline on beta 2-adrenoceptors mediating insulin release from pancreatic beta-cells. Blood glycerol concentration also increased with isoprenaline but blood lactate concentration was unaltered. 5. The present study demonstrates pronounced cardiovascular and metabolic effects of low dose isoprenaline infusions. Differences in the rate of resolution of the changes induced by isoprenaline and by adrenaline seen in previous studies may result from a significant difference in their metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046824     DOI: 10.1042/cs0750285

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

1.  Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.

Authors:  Marc L Reitman; Victor Dishy; Allison Moreau; William S Denney; Chengcheng Liu; Walter K Kraft; Alex V Mejia; Mark A Matson; S Aubrey Stoch; John A Wagner; Eseng Lai
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Continuous intramuscular pH measurement during the recovery from brief, maximal exercise in man.

Authors:  P Allsop; M Cheetham; S Brooks; G M Hall; C Williams
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1990

3.  Integration of multiple imaging platforms to uncover cardiovascular defects in adult zebrafish.

Authors:  Anabela Bensimon-Brito; Giulia L M Boezio; João Cardeira-da-Silva; Astrid Wietelmann; Srinath Ramkumar; Pia R Lundegaard; Christian S M Helker; Radhan Ramadass; Janett Piesker; Arno Nauerth; Clemens Mueller; Didier Y R Stainier
Journal:  Cardiovasc Res       Date:  2022-09-20       Impact factor: 13.081

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.